Clinical trials: Moderate to Severe Asthma
- Condition Moderate to Severe Asthma
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Moderate to Severe Asthma
Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With Asthma
This is a Phase 3b, multicenter, randomized, double-blind, parallel group, placebo-controlled study designed to investigate the potential effect of tezepelumab (210 mg subcutaneous [SC] every 4 weeks [Q4W]) on antibody responses…
- Trial name
- VECTOR (NCT05062759)
- Testing
- Tezepelumab
- Where
- 15 sites in United States
- Volunteers
- 70 people
- Sponsor
- AstraZeneca
Asthma
Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + Tiotropium
The purpose of this trial was to demonstrate that the efficacy of two treatment arms of the fixed-dose combination product QVM149 was non-inferior to the efficacy of the free combination arm of salmeterol/ fluticasone+ tiotropium…
- Trial name
- ARGON (NCT03158311)
- Testing
- QVM149, Salmeterol/fluticasone plus tiotropium
- Where
- 163 sites in Argentina, Chile and 18 more
- Volunteers
- 1,426 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma
This study was designed to assess the safety of indacaterol (300 µg and 600 µg (2 x 300 μg capsules) once daily [od]), compared with salmeterol (50 μg twice a day [b.i.d.]), over 26 weeks, in patients with moderate to severe…
- Trial name
- NCT00529529
- Testing
- Indacaterol 300 μg, Salmeterol 50 μg
- Where
- 126 sites in United States, Argentina and 10 more
- Volunteers
- 805 people
- Sponsor
- Novartis Pharmaceuticals
Persistent Allergic Asthma
Omalizumab in Patients With Moderate to Severe Persistent Allergic Asthma Not Adequately Controlled Despite GINA (2009) Step 4 Therapy
This study will assess the efficacy, safety and tolerability of omalizumab, compared to placebo in 18 to 75 year old Chinese patients with moderate to severe persistent allergic asthma who have inadequate asthma control despite…
- Trial name
- NCT01202903
- Testing
- Omalizumab
- Where
- 39 sites in China
- Volunteers
- 616 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Study Evaluating the Safety and Effects of MN-221 in Subjects With Moderate to Severe Asthma
The purpose of this study is to evaluate the safety and tolerability of MN-221 at two different dosing rates administered through a continuous infusion in subjects diagnosed with moderate to severe asthma.
- Trial name
- NCT00679263
- Testing
- MN-221
- Where
- 4 sites in United States
- Volunteers
- 17 people
- Sponsor
- MediciNova
Asthma
Study to Evaluate the Safety and Efficacy of CAT-354
This is a Phase 2a, randomized, double-blind, placebo-controlled, parallel-arm study to evaluate the efficacy and safety of 3 subcutaneous (SC) treatment regimens of CAT-354 in adult subjects with uncontrolled…
- Trial name
- NCT00873860
- Testing
- CAT-354 150 mg, CAT-354 300 mg, CAT-354 600 mg
- Where
- 57 sites in Bulgaria, Germany and 3 more
- Volunteers
- 357 people
- Sponsor
- MedImmune LLC
Asthma
Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma
Randomized, multi-center, double-blind, placebo-controlled, parallel group, proof of-concept study with RPT193 in subjects with T2-high, moderate-to-severe asthma who are partially controlled on medium or high doses of inhaled…
- Trial name
- NCT05935332
- Testing
- RPT193
- Where
- 29 sites in United States, Bulgaria and 2 more
- Volunteers
- 38 people
- Sponsor
- RAPT Therapeutics, Inc., a member of the GSK plc group of companies
Allergic Rhinitis, Asthma
An Exploratory Study of Nasonex in Patients With Moderate to Severe Persistent Allergic Rhinitis and Intermittent Asthma
The primary objective of this study is to explore the efficacy of Nasonex (mometasone furoate nasal spray) in comparison with placebo in improving the quality of life of subjects with moderate to severe persistent allergic…
- Trial name
- NCT00599027
- Testing
- Mometasone furoate nasal spray (MFNS)
- Volunteers
- 51 people
- Sponsor
- Organon and Co
Asthma
Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Severe Asthma
An unmet medical need exists for patients with moderate and severe asthma who continue to demonstrate symptoms despite being on standard of care medications, and are not eligible for other biologic therapies developed or in…
- Trial name
- NCT03299686
- Testing
- CJM112
- Where
- 29 sites in United States, Argentina and 6 more
- Volunteers
- 118 people
- Sponsor
- Novartis Pharmaceuticals
Asthma
Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe Asthma
This was a parallel, Phase 2, global, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, four-arms study for treatment.
- Trial name
- TIDE-asthma (NCT05421598)
- Testing
- Amlitelimab
- Where
- 113 sites in United States, Argentina and 12 more
- Volunteers
- 437 people
- Sponsor
- Sanofi
Asthma
A Study of Itolizumab (EQ001) to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity in Uncontrolled Asthma
This is a multi-center study to evaluate the safety, tolerability, PK, PD, and clinical activity of itolizumab (EQ001) in subjects with moderate-to-severe asthma.
- Trial name
- EQUIP (NCT04007198)
- Testing
- EQ001
- Where
- 13 sites in Australia, New Zealand
- Volunteers
- 18 people
- Sponsor
- Biocon Limited
Asthma
Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up)
Primary Objective: To describe the long-term safety of dupilumab in treatment of participants with moderate to severe asthma who completed the previous asthma clinical trial (TRAVERSE-LTS12551).
- Trial name
- NCT03620747
- Testing
- Dupilumab SAR231893 (REGN668)
- Where
- 132 sites in United States, Argentina and 8 more
- Volunteers
- 393 people
- Sponsor
- Sanofi
Asthma
Study to Evaluate the Pharmacokinetics of Tezepelumab in Children With Asthma
This study will evaluate the pharmacokinetic (PK) profile of a single subcutaneous (SC) dose of tezepelumab in children aged ≥ 5 to 11 years with asthma.
- Trial name
- TRAILHEAD (NCT04673630)
- Testing
- Tezepelumab
- Where
- 6 sites in Hungary, South Africa and 1 more
- Volunteers
- 18 people
- Sponsor
- AstraZeneca
Asthma
Study to Assess the Efficacy and Safety of MEDI3506 in Adults With Uncontrolled Moderate-to-severe Asthma
Study D9181C00001 is a Phase II, randomised, double-blind, placebo-controlled, parallel group, proof of concept study to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of MEDI3506 in adult participants…
- Trial name
- FRONTIER-3 (NCT04570657)
- Testing
- MEDI3506
- Where
- 65 sites in United States, Argentina and 5 more
- Volunteers
- 250 people
- Sponsor
- AstraZeneca
Asthma
4 Week 2 Way Crossover Double Blind Treatment Phase With Combivent CFC Versus Albuterol Followed by a 4 Week Open Label Combivent Respimat When All Drugs Are Used for Symptom Relief as Needed in Pts With Moderate to Severe Asthma
The primary goal of this trial is to compare the efficacy and safety of COMBIVENT CFC MDI with albuterol HFA MDI, the current standard reliever medication in asthma.
- Trial name
- NCT00818454
- Testing
- Combivent CFC MDI, Albuterol HFA MDI, Respimat Combivent
- Where
- 41 sites in United States
- Volunteers
- 226 people
- Sponsor
- Boehringer Ingelheim
Asthma
A Study to Compare the Efficacy and Safety of Different Dosings of Olodaterol Administered With the Respimat® Inhaler in Patients With Moderate to Severe Asthma
This study will compare efficacy and safety of different regimens of olodaterol administration in asthma (once daily, twice daily) with placebo in a complete cross-over design each within one of the two daily dose groups (medium…
- Trial name
- NCT01311661
- Testing
- Olodaterol low daily dose twice daily, Olodaterol medium daily dose twice daily
- Where
- 36 sites in United States, Austria and 4 more
- Volunteers
- 206 people
- Sponsor
- Boehringer Ingelheim
Asthma
An Evaluation Of PF-03715455 In Moderate To Severe Uncontrolled Asthma
The study proposes to evaluate the safety and efficacy of PF-03715455 in moderate to severe asthma when added to standard of care and during staged withdrawal of background therapy.
- Trial name
- NCT02219048
- Testing
- PF-03715455
- Where
- 28 sites in United States
- Volunteers
- 51 people
- Sponsor
- Pfizer
Moderate-to-Severe Asthma
Effect of KB003 in Subjects With Asthma Inadequately Controlled by Corticosteroids
This study will evaluate the safety, tolerability and efficacy of a single dose level of KB003 in subjects with inadequately controlled asthma.
- Trial name
- KB003-04 (NCT01603277)
- Testing
- Anti-GM-CSF Monoclonal Antibody 400mg
- Where
- 70 sites in United States, Australia and 4 more
- Volunteers
- 160 people
- Sponsor
- Humanigen, Inc.
Asthma
Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants
Primary Objective: To evaluate the effects of SAR440340 with or without dupilumab, compared to placebo, on reducing the incidence of "loss of asthma control" (LOAC) events.
- Trial name
- NCT03387852
- Testing
- SAR440340, Dupilumab, Fluticasone or Fluticasone/salmeterol combination
- Where
- 71 sites in United States, Argentina and 6 more
- Volunteers
- 296 people
- Sponsor
- Sanofi
Asthma
A Study of Omalizumab (Xolair) in Subjects With Moderate to Severe Persistent Asthma (EXTRA)
This is a multicenter, randomized, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of subcutaneously administered Xolair as add-on therapy for the treatment of subjects aged 12-75 years old…
- Trial name
- NCT00314574
- Testing
- omalizumab (Xolair), corticosteroids, long-acting beta-agonists
- Volunteers
- 850 people
- Sponsor
- Genentech, Inc.